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Abstract
Current therapy for human immunodeficiency virus (HIV-1) infection relies primarily on the administration of anti-
retroviral nucleoside analogues, either alone or in combination with HIV-protease inhibitors. Although these drugs
have a clinical benefit, continuous therapy with the drugs leads to drug-resistant strains of the virus. Recently, sig-
nificant progress has been made towards the development of natural and synthetic agents that can directly inhibit
HIV-1 replication or its essential enzymes. We previously reported on the pharmacological cyclin-dependent kinase
inhibitor (PCI) r-roscovitine as a potential inhibitor of HIV-1 replication. PCIs are among the most promising novel
antiviral agents to emerge over the past few years. Potent activity on viral replication combined with proliferation
inhibition without the emergence of resistant viruses, which are normally observed in HAART patients; make PCIs
ideal candidates for HIV-1 inhibition. To this end we evaluated twenty four cdk inhibitors for their effect on HIV-1
replication in vitro. Screening of these compounds identified alsterpaullone as the most potent inhibitor of HIV-1
with activity at 150 nM. We found that alsterpaullone effectively inhibits cdk2 activity in HIV-1 infected cells with a
low IC50 compared to control uninfected cells. The effects of alsterpaullone were associated with suppression of
cdk2 and cyclin expression. Combining both alsterpaullone and r-roscovitine (cyc202) in treatment exhibited even
stronger inhibitory activities in HIV-1 infected PBMCs.
Background
Human immunodeficiency virus type 1 (HIV-1) is the
causative agent of Acquired Immunodeficiency Syn-
drome (AIDS). Current therapies are capable of control-
ling viral infection but do not represent a definitive
cure. The virus has proven to be capable of developing
resistance to therapy, evading the immune response,
altering cellular immune function and protecting
infected cells from apoptosis. HIV-1 is inherently cap-
able of accomplishing these functions with a limited
genome that expresses only nine proteins. As such, the
HIV-1 must make extensive use of cellular pathways
and subvert native molecular processes for its own
purposes.
Expression of the HIV-1 proviral genome requires
host cell transcription factors as well as the Tat viral
transactivator (reviewed in [1-3]). Tat stimulates forma-
tion of full-length transcripts from the HIV-1 promoter
[4,5] by promoting efficient transcriptional elongation
(reviewed in [1,2]). Tat interacts with the bulge of the
transactivation response element (TAR) RNA, a hairpin-
loop structure at the 5’-end of all nascent viral tran-
scripts [6-9]. Full functional activity of Tat requires host
cell cofactors, which interacts with the loop of TAR
RNA hairpin (reviewed in [1,2]) as well as other site on
the LTR. Tat also associates with a protein kinase that
phosphorylates the C-terminal domain (CTD) of RNA
Polymerase II (RNA Pol II) called Tat associated kinase
(TAK) [10]. The CTD consists of heptapeptide repeats,
Tyr
1-Ser
2-Pro
3-Tyr
4-Ser
5-Pro
6-Ser
7, which are phos-
phorylated on serine 2 (Ser-2) and serine 5 (Ser-5) dur-
ing transcription [11,12]. Recently, serine 7 (Ser-7) has
b e e ns h o w nt ob ep h o s p h o r y l a t e db yc d k 7[ 1 3 , 1 4 ] .P r e -
viously, it has also been shown that partially purified
TAK and the loop-binding factor represent the same
protein complex, cdk9/cyclin T1 [15-17]. Tat associates
with cdk9 [16,17] through interaction with cyclin T1
which interacts with the TAR RNA loop structure [15].
Tat interacts with human cyclin T1 through a critical
cysteine and the presence of a different amino acid in
this position in rodent cells renders Tat transactivation
inefficient [18,19]. In an in vitro transcription system,
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phosphorylated RNA Pol II [20]. In kinase assays, Tat
induces phosphorylation of CTD by cdk9, which
requires the N-terminal domain (amino acids 1 to 48)
and the arginine-rich motif (amino acids 49-57) of Tat
[21]. Tat may also induce TFIIH-associated cdk7 to
phosphorylate Ser-5 in the pre-initiation complex
[22,23]. Subsequently, TFIIH dissociates from the preini-
tiation complex and this dissociation relieves inhibition
of cdk9 autophosphorylation [24], which is required for
efficient binding of cdk9/cyclin T1 to TAR RNA [21].
Recently, a growing body of evidence has indicated the
role of yet another cyclin/cdk complex, namely cyclin
E/cdk2, in Tat activated transcription. Cyclin E/cdk2 is
the major cyclin/cdk complex whose maximal activity is
observed at the late G1/S boundary. Cyclin E/cdk2 has
been shown to be important in the transition of G1/S
by regulating the release of Rb sequestered factors,
including E2F [25]. Given the importance that the G1/S
checkpoint plays in viral replication, it is not surprising
that HIV-1 viral proteins, like Tat, have been shown to
modulate G1/S activity. From our own studies, we have
observed the increased kinase activity of cyclin E/cdk2
complexes in HIV-1 latently infected cells due to the
loss of the natural cdk inhibitor p21/waf1 [26]. Cdk
inhibitor p21/waf1 is normally induced by p53 upon cel-
lular stress and regulates the G1/S transition by inhibit-
ing the activity of cyclin/cdk complexes. Studies from
our lab have shown that HIV-1 latently infected T cells
do not induce expression of p21/waf1 after injury to the
host cell. For instance, flow cytometric analysis revealed
that upon g-irradiation, these cells proceeded into the S
phase and apoptosed. The lack of p21/waf1 expression
was attributed to the physical and functional interaction
of Tat with p53, resulting in the inactivation of p53
[26,27]. To further validate the significance of the G1/S
and cdk2 in HIV-1 transcription in vivo, HLM-1 cells
(HIV-1
+/Tat
-), were first transfected with wild type Tat
and were subsequently blocked with either hydroxyurea
(a general G1/S blocker) or nocodazole (a general M
phase blocker). Supernatants were collected every third
day and analyzed for the presence of the gag/p24 anti-
gen. HIV-1 attained peak viral replication between days
9 and 12 for those cells blocked with nocodazole, while
G1/S blockage by hydroxyurea resulted in the dramatic
inhibition of virion production [28]. Collectively, these
studies pointed to two important findings. One, that
HIV-1 in latently infected cells down modulates the nat-
ural cdk inhibitor p21/waf1 (i.e., by Tat binding to p53
and/or other related mechanisms), and in turn is able to
control the primary cdk target such as cyclin E/cdk2
complex, and second, that G1/S kinases, such as cdk2/
cyclin E, could be targeted for inhibition of HIV-1 repli-
cation using drugs that mimic the natural cdk inhibitors.
Over the past few years, pharmacological cdk inhibi-
tors (PCIs) have been reported to prevent viral replica-
tion in vitro [29]. The underlying mechanism of action,
inhibition of cellular rather than viral targets, is unli-
kely to favor the appearance of resistant strains and
could potentially be efficient against several unrelated
viruses. Numerous viruses require active cdks for their
replication and some viruses actually encode their own
cyclins, thereby regulating their host cell cycle [30].
Cdks are required for replication of viruses that multi-
ply only in dividing cells, such as adeno- and papillo-
maviruses. Recently, cdks have also been shown to be
required for the replication of viruses that multiply in
non-dividing cells, such as HIV-1 and herpes simplex
virus types 1 and 2 (HSV-1 and -2) [31,32]. In these
experiments PCIs were shown to have potent antiviral
activity in vitro against HIV-1, HSV-1 and -2, human
cytomegalovirus, varicella-zoster virus, and to inhibit
specific functions of other viruses [33]. Since two PCIs,
flavopiridol and roscovitine, have been proven to be
non-toxic in human clinical trials against cancer [34],
PCIs, therefore may be useful as antivirals. As signifi-
cant advantage of PCI are its activity against many
viruses, including drug-resistant strains of HIV-1 and
HSV-1 [35,36]. Furthermore, the antiviral effects of a
PCI and a conventional antiviral drug could have an
additive effect. Roscovitine is the second-best-studied
PCI in vivo (after flavopiridol) and it has proven
non-toxic in several animal models [37,38]. The
purified r-enantiomer of roscovitine (cyc202) has
entered human clinical trials. In phase I clinical trials,
r-roscovitine has proven to be orally bioavailable and
to have no acute toxicity [39].
Other class of inhibitors including paullones repre-
sents a novel class of small molecule cdk inhibitors.
Paullones constitute a new family of benzazepinones
with promising antitumoral properties. They were
described as potent, ATP-competitive, inhibitors of the
cell cycle regulating cdks [40]. Alsterpaullone, the most
active paullone, was demonstrated to act by competing
with ATP for binding to GSK-3b. Alsterpaullone inhibits
the phosphorylation of tau in vivo at sites which are
typically phosphorylated by GSK-3b in Alzheimer’sd i s -
ease [41]. Alsterpaullone also inhibits the cdk5/p35-
dependent phosphorylation of DARPP-32 in mouse
striatum slices in vitro [41]. This dual specificity of paul-
lones may turn these compounds into very useful tools
for the study and possibly treatment of neurodegenera-
tive and proliferative disorders [42]. Replacement of the
9-bromo substituent of kenpaullone by a 9-cyano or
9-nitro group produced a substantial increase in
enzyme-inhibiting potency [43]. Interestingly, alsterpaul-
lone has been selected for preclinical development in a
NCI program [44].
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potent inhibitory effect on HIV-1 infected cells. Its
mechanism of action has previously been attributed to
inhibition of cdk2/cyclin A complex at the G1/S as well
as few other kinases. Here, the primary mode of the
inhibition in infected cells appears to be at the protein
levels of cyclins which ultimately result in apoptosis of
HIV-1 infected cells. Finally, low concentration of two
drugs combined, alsterpaullone and r-roscovitine, favor
inhibition of the HIV-1 transcription in primary cells.
Results
Screening of twenty-four inhibitors in HIV-1 infected and
uninfected cells
We analyzed the effects of twenty four different cdk
inhibitors in HIV-1 infected cells ACH2, OM10.1, J1-1,
U 1a n du n i n f e c t e dc e l l si n c l u d i n gC E M ,J u r k a ta n d
U937 cells. For the initial set of screenings, cells were
cultured in medium (0.5 × 10
6 cells/well) with inhibitors
at 10 μM concentration. After 72 hours of culture, cell
viability was determined using trypan blue exclusion
method. Results of such a screen are shown in Table 1
where percent of live cells are indicated after various
drug treatments. A total of ~100 cells that were not
clumped together were counted and scored with trypan
blue. The inhibitors were classified into three categories:
high, moderate or poor selectivity according to their cel-
lular viability in both HIV-1 infected and uninfected
cells. Among the 24 inhibitors, alsterpaullone proved to
be the drug with the highest selectivity in promoting
cell death in HIV-1 infected cells, followed by indirubin-
3-monoxime, indirubin-3-monoxime-5-indo, purvalanol
A, and r-roscovitine. Along these lines, we have pre-
viously shown that r-roscovitine (cyc202) is able to inhi-
bit virus replication both in primary cells as well as in
cells lines in vitro. Also, there were varying levels of cell
death in uninfected treated cells; however drugs in the
high selectivity category were generally more active
toward HIV-1 infected cells. All infected cells expressed
some levels of doubly or singly spliced messages when
cultured in 10% fetal calf serum. Collectively, these pre-
liminary cell based screening data indicated that some
cdk inhibitors may be more selective toward HIV-1
infected cells and promote cell death in vitro as com-
pared to uninfected cells.
Alsterpaullone exhibited an inhibition of cell viability and
promoter activity in HIV-1 infected cells
Following the identification of alsterpaullone as the drug
with the highest selectivity in inhibiting HIV-1 infected
Table 1 Screening of various cdk inhibitors and related molecules in HIV-1 infected cells
Selectivity Name ACH2 J1.1 OM10.1 U1 CEM Jurkat U937
Infected Uninfected
High Alsterpaullone (10 μM) 11 25 15 37 89 92 88
Indirubin-3’-monoxime (10 μM) 22 32 35 38 84 83 87
Indirubin-3’-monoxime-5’-indo (10 μM) 24 35 37 52 80 82 80
Purvalanol A (10 μM) 27 53 48 54 78 79 77
r-Roscovitine (10 μM) 32 40 30 35 75 85 82
Moderate CGP 74514A (10 μM) 42 56 54 52 72 77 70
Aloisine A (10 μM) 50 52 59 53 72 70 68
Bohemine (10 μM) 58 65 67 50 72 80 50
2,6-Diaminopurine (10 μM) 64 75 77 74 75 68 65
2,6-Dichloropurine (10 μM) 75 74 76 75 69 71 71
Flavone (10 μM) 86 85 83 85 75 67 50
Poor 6-Benzyloxypurine (10 μM) 90 91 92 88 68 72 54
Compound 52 (10 μM) 95 97 94 95 97 97 98
9-Cyanopaullone (10 μM) 97 97 95 98 95 96 97
6-Dimethylaminopurine (10 μM) 95 95 96 97 97 95 96
Indirubin-3’-monoxime-5’-sulphonic acid (10 μM) 95 95 96 96 96 96 95
Iso-olomoucine (10 μM) 96 96 96 97 95 95 97
N-6-(Δ2-Isopentenyl)-adenine (10 μM) 96 96 98 99 95 98 96
Kenpaullone (10 μM) 94 97 95 95 95 95 95
Olomoucine (10 μM) 95 95 96 96 95 95 95
Olomoucine N9-isoppropyl (10 μM) 96 95 95 96 95 96 96
s-Roscovitine (10 μM) 95 95 95 94 95 98 96
WHI-P180 (10 μM) 95 97 98 99 98 97 98
SC-514 (10 μM) 95 98 99 99 98 96 99
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dependent manner on HIV-1 infected cells at different
concentrations including 0.01, 0.1, 0.5, 1.0, and 5 μM.
A ss h o w ni nF i g u r e1 A ,a f t e rc e l lt r e a t m e n tw i t hv a r -
ious concentrations for 3 days, the inhibition of cell
viability in HIV-1 infected cells was more pronounced
when compared to the control uninfected group. We
normalized for the percent of live cells for each cell
type at time zero and performed triplicates for each
concentration. The CC50 of alsterpaullone was deter-
mined to be at ~0.10-0.25 μM for the HIV-1 infected
cells and ~5 μM for the uninfected cells. To further
refine and validate the results in panel A, we used an
MTT assay in cells treated with a fixed concentration
of the drug (0.25 μM). Results in panel B show that by
and large, infected cells are more susceptible to alster-
paullone as compared to uninfected cells. Finally we
asked whether alsterpaullone was able to inhibit Tat
Figure 1 Infected cell viability and Tat-induced HIV-1 LTR transcription are inhibited by alsterpaullone. A) HIV-1 infected cells (ACH2,
OM10.1, and U1) and corresponding control uninfected cells (CEM, Jurkat and U937) were plated in 24-well plates and cultured with increasing
concentrations of alsterpaullone (0.01-5 μM). After 48 hours, the cells were stained by trypan blue and percent viability calculated with a
hemocytometer. Assays were performed in triplicate, average values and standard deviations are shown. B) MTT assays were used for HIV-1
infected and corresponding control uninfected cells. Cells were seeded in a 96-well plate and cultured with 0.25 μM alsterpaullone, and 48 hours
later, absorbance was read at 570 nm. Percent viability assays were performed in triplicate and average values and standard deviations are
shown. C) TZM-bl cells were transfected with 1 μg of Tat and treated the next day with DMSO or the indicated compound (50, 150, or 300 nM).
Cells were processed 48 hours post drug treatment for luciferase assays. Assays were performed in triplicate, average values and standard
deviations are shown.
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bl cells contain an integrated HIV-1 LTR-luciferase
reporter construct and were transfected with Tat and
treated with various concentrations of alsterpaullone,
and indirubin-3’-monoxime-5’-indo as control. Lucifer-
ase assays revealed that alsterpaullone, indirubin-3’-
monoxime-5’-indo and purvalanol A (data not shown)
decreased viral transcription of the fully chromatinized
promoter at an approximate IC50 of 150 nM or less
(Figure 1C). Collectively, these results imply that
alsterpaullone can selectively inhibit HIV-1 promoter
activity and kill infected cells in a dose dependent
manner.
Effect of alsterpaullone on cdk2/cyclinA activity in HIV-1
infected and uninfected cells
Alsterpaullone was previously tested on a variety of
highly purified kinases in vitro [41]. Kinase activities
were assayed with appropriate substrates, cold ATP
(15 μM) as control, and in the presence of increasing
concentrations of alsterpaullone. The IC50 values were
obtained from the dose-response curves. Most kinases
tested were poorly or not inhibited (IC50 >1 0μM).
However, in addition to the previously reported effect
on cdk1/cyclin B, alsterpaullone was found to inhibit
cdk2/cyclin A, cdk2/cyclin E, cdk5/p35 and GSK-3a/
GSK-3b (IC50 v a l u e so f1 5 ,2 0 0 ,4 0a n d4n Mr e s p e c -
tively). We therefore asked which of these various cdk/
cyclin complexes in HIV-1-infected cells were most
sensitive to alsterpaullone. A typical kinase assay from
HIV-1 infected (OM10.1 cells) and uninfected cells
(Jurkat and CEM cells) is shown in Figure 2. Alster-
paullone (0.01, 0.1, 0.5, 1, 5, and 25 μM) treated cells
were immunoprecipitated with cyclin A antibody, iso-
lated complexes were washed and added to kinase
reactions containing histone H1 as a substrate. As seen
in Figure 2A, 0.5 μM of alsterpaullone completely
inhibited the cdk2 kinase activity from infected cells
when using histone H1 as a substrate (Figure 2A, lane
3). The cdk2 activity however was inhibited at much
higher alsterpaullone concentrations in uninfected cells
(Figure 2B, lanes 4-6). As a negative control, kinase
assays were performed with immunoprecipitation with
anti-IgG antibody with minimal background activity
(data not shown). To further validate these results, we
performed kinase assays with fixed concentration of
alsterpaullone (0.5 μM) and found a reproducible pat-
t e r nw h e r ek i n a s ea c t i v i t yw as severely inhibited in
immunoprecipitates from infected and not the unin-
fected cells (Figure 2C). Collectively, these data indi-
cates that cdk2 in HIV-1 infected cells may be either
more sensitive to alsterpaullone or the expression
levels in these cells may have changed following drug
treatment.
Inhibitory effect of alsterpaullone on cyclin/cdk
expression
Because alsterpaullone is a purine analog, it can com-
pete with the ATP binding site in cdks and has been
shown to inhibit cdk2/cyclin E and cdk2/cyclin A kinase
activities with an IC50 at 0.035 and 0.07 μM, respectively
when using in vitro kinase assays. To examine whether
alsterpaullone inhibits expression of these cell cycle reg-
ulatory proteins in HIV-1 infected cells, we determined
the levels of cdk2, cyclin E, cyclin A, and other kinases
by western blot analysis. As shown in Figure 3A, the
levels of cdk2, and cyclin A expression declined drama-
tically at 0.5 μM of alsterpaullone treatment in infected
OM10.1 cells (Figure 3, lane 4). The level of cyclin T
and E expression also declined to lower levels in these
cells. Therefore, in relations to the previous IP/kinase
assays (Figure 2), these results indicate that alsterpaul-
lone down-regulates the amount of functional cdk2/
cyclin A complex by reducing the expression/protein
levels in HIV-1 infected as compared to uninfected cells.
Next, to determine the efficacy of alsterpaullone in
induction of apoptosis in infected cells, we analyzed two
markers of apoptosis, namely the cleavage of caspase-3
and PARP using western blot analysis. Both infected and
uninfected cells were treated with various concentration
of the drug and whole cell extracts were processed for
presence of cleaved products. As shown in Figure 3B,
the levels of both cleaved PARP and caspase-3 increased
in infected cells at 0.5 and 1 μM concentrations. Impor-
tantly, alsterpaullone treatment did not significantly
induce cleavage of caspase-3 and PARP in uninfected
Jurkat cells. Collectively these results indicate that treat-
ment of HIV-1 infected cells with low concentrations of
alsterpaullone may result in increase of apoptosis mar-
kers in infected cells with little to no apparent apoptosis
in uninfected cells.
Effect of alsterpaullone on the cell cycle and apoptosis in
infected and uninfected cells
We next were interested in determining whether the cell
cycle stage of infected cells could be altered after drug
treatment. For this we treated both uninfected (Jurkat
and CEM) as well as infected (OM10.1 and ACH2) cells
with alsterpaullone (0.5 μM) for 48 hours followed by
FACS analysis using propidium iodide staining. We had
initially performed a pilot experiment with time and
drug titrations to find a window of time where cells
would begin the process of apoptosis, but no completely
progress into final stages of apoptosis (data not shown).
Results in Figure 4 show that Jurkat or CEM uninfected
cells were not dramatically altered in their cell cycle
stages before or after treatment. However, both OM10.1
and ACH2 infected cells were altered in their G1, S, and
sub G1 (apoptosis) peaks following drug treatment. Both
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population, an increase in S phase, as well as a dramatic
increase in apoptotic peaks. No viral particles as assayed
by presence of RT were observed in the supernatant
after drug treatment (data not shown). These results
imply that the apoptotic peaks (more than 10 fold in
each infected cell type) could be either coming from the
G1 population or partly from the S phase population
(loss of G1/S check point). The apparent loss of check
point control may be from inactive p53 function and a
decrease in p21/waf1 levels in both infected cell types
[45-47]. Collectively, these results indicate that the drug
effect is mostly specific to G1 and S phase population in
HIV-1 infected cells.
Effect of alsterpaullone in PBMC infected cells
We next performed an infection of PHA and IL-2 acti-
vated PBMCs and treated these cells with various con-
centrations of alsterpaullone for up to 18 days. In this
primary cell system, both the effect of HIV-1 replication
(using RT assay) and the percent of live cells (trypan
blue exclusion) were used to monitor the infection. As
seen in Figure 5A, 1 μM of alsterpaullone almost com-
pletely inhibited virus replication at day 12 and inhibited
replication by approximately 50% at day 18 in two inde-
pendent experiments. It is important to note that drug
treatment was performed only once in these cells (addi-
tion at day 0). Furthermore, concentrations up to 5 μM
did not alter the percent of live cells in either uninfected
Figure 2 Alsterpaullone inhibition of cdk2/cyclin A complex in HIV-1 infected cell. A) Equal amount (2 mg) of cytoplasmic proteins from
alsterpaullone-treated ACH2 and OM10.1 cells were immunoprecipitated with anti-cyclin A antibody and the cdk2 activity was examined by in
vitro kinase assay using histone H1 as a substrate. Alsterpaullone at various concentrations (0.01, 0.1, 0.5, 1, 5, and 25 μM) were used in treatment
of cells. The [g-
32P]-labeled histone H1 was visualized by autoradiography. Alsterpaullone completely inhibits cdk2 kinase activity in infected cells
at 0.5 μM (lane 2). B) Similar to panel A, but used extracts from uninfected cells for IP. Alsterpaullone moderately inhibited cdk2 activity in
uninfected CEM and Jurkat cells but only at high concentrations (lanes 4-6). C) Effect of low concentration of alsterpaullone in kinase assay.
Similar to panel A and B, a low concentration of alsterpaullone (0.5 μM) was used in kinase inhibition studies. Infected (ACH2 and OM10.1) as
well as uninfected control (CEM and Jurkat) cell lysates were used for these assays. Lanes 1, 3, 5 and 7 were cells treated with DMSO and lanes
2, 4, 6, and 8 were treated with alsterpaullone. Results are triplicate experiment of using cyclin A IP as the Kinase and histone H1 as the
substrate.
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centrations of the drugs are not toxic to primary acti-
vated cells.
Next, we asked whether low concentrations of r-ros-
covitine and alsterpaullone could potentially inhibit
virus replication in primary cells. We have previously
shown that r-roscovitine (cyc202) is able to inhibit virus
replication both in primary cells as well as cells lines
[48]. The IC50 in latent infected cells was from 0.36 μM
to 1.8 μM depending on the cell type. Here we utilized
a combination of a low 0.01 μM concentration of each
r-roscovitine and alsterpaullone, which normally would
not inhibit viral replication when used in monotherapy.
Results in Figure 5C indicate that the addition of low
concentrations of both drugs effectively inhibited a field
isolate of HIV-1 in PBMC infections. The combination
of these two drugs at such low concentrations had no
apparent toxic effects in active PBMCs (data not
Figure 3 Alsterpaullone inhibition of cdk2 and cyclin expression in HIV-1 infected and uninfected cells. A) HIV-1 infected OM10.1 and
uninfected Jurkat cells were treated with alsterpaullone (0.01, 0.1, 0.5, and 1 μM) for 48 hours. Total cell extracts (25 μg) were subjected to
western blot analysis for cdk2, cyclin A, cyclin E, cyclin T, GSK-3a, GSK-3b, and actin. B) Similar to panel A, Jurkat and OM10.1 cells were treated
with various concentrations of alsterpaullone and cell extracts were processed for presence of apoptosis markers (cleaved PARP and caspase-3
products). b-actin was used as internal control for all westerns. Both processed and cleaved PARP and caspase-3 were observed in higher
concentrations of alsterpaullone treated OM10.1 infected cells.
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bitors that target the G1/S (cyc202) and early S (alster-
paullone) phases may effectively block viral replication
in primary cells when infected with HIV-1 field isolates.
Discussion
In contrast with the latest progress in the understanding
of HIV-1 infection, its pathogenesis and mechanism of
action-especially in relation to therapies, are still at its
infancy. However few well established pathways includ-
ing cell signaling involving kinases and markers of cell
cycle progression have been shown to be tightly regu-
lated in HIV-1 infected cells and therefore provide
viable targets for treatment. Cdks are attractive targets
for drug development since their activity, required for
the correct timing and ordering of the cell cycle, is fre-
quently deregulated in cancer. Numerous small mole-
cule inhibitors of cdks have been identified and proven
Figure 4 Alsterpaullone induces apoptosis in HIV-1 infected cells. For fluorescence-activated cell sorting (FACS), both untreated and treated
Jurkat, OM10.1, CEM and ACH2 cells were stained with a mixture of propidium iodide buffer followed by cell sorting analysis. The left panels
show mock-treated cells (DMSO) and the right panels correspond to alsterpaullone treated cells (0.5 μM) for 48 hours. A higher percentage of
apoptotic cells were observed in treated OM10.1 (~44%) and ACH2 (~48%) cells as compared to untreated, uninfected Jurkat (~7%) and CEM
(~3%) counterparts.
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Page 8 of 14Figure 5 Effect of alsterpaullone in PBMC infection. A) Phytohemagglutinin (PHA) and IL-2 activated PBMCs were kept in culture for 2 days
prior to infection. Approximately 5 × 10
6 PBMCs were infected with pNL4-3 (MOI:1). Alsterpaullone treatment (0.01-5.0 μM) was used (only once)
immediately after the addition of the fresh medium. Samples were collected every sixth day and stored at -20°C for further analysis (RT assay).
Both PHA and IL-2 were added to media every 3 days. Viral supernatants (10 μl) were incubated in a 96-well plate with reverse transcriptase (RT)
reaction mixture, incubated overnight at 37°C, spotted, washed, dried, and then counted using a Betaplate counter. B) Cells were also counted
(~100/date) for viability using trypan blue staining method. C) Approximately 5 × 10
6 activated PBMCs were infected with primary HIV-1 strain
(THA/92/00NSI), and then treated after viral adsorption (12 hrs) with either mock (DMSO) or cyc202 (0.01 μM) or alsterpaullone (0.01 μM) or with
the combination of both drugs. Samples were collected every six days (0, 6, 12, 18 and 24 days) and stored at -20°C or p24 assay.
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increased sensitivity of the transformed cells to inhibi-
tors and to the changes that are associated with cdk
activity and levels in a cell. However the consequences
of cdk inactivation are complex and can result in dispa-
rate outcomes depending on the tumor type and the
genetic context that drives their expression.
We investigated whether targeting the cdk/cyclin axis
could inhibit the growth of HIV-1 infected cells and
assessed this hypothesis using multiple cdk inhibitors.
Along these lines, we searched for various inhibitors tar-
geting multiple cdk/cyclin pathways using published lit-
erature and our own search by means of small libraries
of compounds. We selected first generation inhibitors
with low-high IC50 in various cell types and identified
their cell growth inhibition efficiencies in HIV-1 infected
and uninfected cells. Results in Table 1 clearly show that
there are various compounds that specifically target
HIV-1 infected cells. In the high selectivity group, alster-
paullone demonstrated the best selectivity to block via-
bility of all HIV-1 infected cells tested and little
blockage to control cells at the concentrations tested.
Indirubin-3’-monoxime, indirubin-3’-monoxime-5-indo,
purvalanol A and r-roscovitine also inhibited growth of
infected cells to varying degree. Consequently, we
decided to focus and study the mechanism of alsterpaul-
lone in the current manuscript.
Our results with titration of alsterpaullone showed
that HIV-1 infected cells were more vulnerable to apop-
tosis in a concentration dependent manner. Many of
these so called latent infected cells harbor various forms
of virus and have a certain level of leakiness and expres-
sion of singly and doubly spliced messages in the
absence of any inducers. Therefore, there is viral tran-
scription in many of these cells especially when they are
treated and fed with 10% fetal bovine serum, which pro-
vides enough cytokine and growth factor signaling to
produce leaky viral transcription in these cells.
We then focused on the cdk2/cyclin A complex since
it has been shown to be involved in early S phase transi-
tion of cell cycle, is important for cellular DNA synth-
esis, and is a target of alsterpaullone. Interestingly, when
we used immunoprecipitation to detect the kinase activ-
ity of endogenous cdk2/cyclin A, we found great inhibi-
tion with alsterpaullone in infected cells. However, upon
western blot analysis of cdk2 and other cyclins in drug
treated cells, we found lower levels of cdk2 and cyclins
in infected cells and not in uninfected cells. Downregu-
lation of cdk2, cyclin A, cyclin T, and cyclin E in
infected cells is interesting and may indicate that cdk/
cyclin complexes in HIV-1 infected cells are inherently
different in their behavior, partner binding or post-
translational modifications, among other factors, which
may contribute to its high sensitivity to alsterpaullone.
Consistent with the cleaved caspase-3 and PARP levels,
FACS analysis also showed a dramatic difference in
infected versus uninfected cells. Results in Figure 4
clearly show that, in infected cells (OM10.1 and ACH2),
the G1 phase population has decreased and the S phase
p o p u l a t i o nh a si n c r e a s e d ,a sw e l la sa ni n c r e a s eo f
almost ten-fold in the apoptotic population. This implies
that the G1/S checkpoint in infected cells is either non-
existent or severely defective which may be the ultimate
mechanism of how these cdk inhibitors kill HIV-1
infected cells. Importantly, there was no viral release
after treatment of the infected cells with alsterpaullone
(data not shown) even though the cells were apoptosing.
When using primary cells, we found similar IC50 of
inhibition in infected PBMCs as well as an additive effect
of r-roscovitine (cyc202) with low concentrations of alster-
paullone. Both of these drugs, which target G1/S and the
early S phase at low concentrations, do not kill infected or
uninfected cells. However, the addition of low concentra-
tions of both drugs to the infected cells selectively inhibits
viral replication in primary cells. We therefore concluded
that to inhibit HIV-1 activated transcription, one may
need to use multiple cdk inhibitors that inhibit critical
cdk/cyclin complexes that are needed for HIV-1 transcrip-
tion, and low concentrations of these drugs may have a
synergistic effect in infected cells.
Finally, alsterpaullone is also a potent GSK-3a/GSK-3b
inhibitor [49]. GSK-3a/GSK-3b are implicated in the reg-
ulation of glycogen synthesis, the Wnt signaling pathway,
cell cycle control, transcriptional regulation, and apopto-
sis [50]. The ability GSK-3a/GSK-3b to regulate this vast
array of cellular processes may be related to its numerous
substrates including, glycogen synthase, axin, b-catenin,
APC, cyclin D1, c-Jun, c-myc, C/EBPa/b,N F A T c ,R e l A
and CREB to name a few [50,51]. Interestingly, Tat
induces GSK-3b activity, which can be reversed by the
addition of the GSK-3b inhibitor lithium [52]. Further-
more, the GSK-3b inhibitors lithium and VPA can pro-
tect against Tat and gp120 mediated neurotoxicity
[53-55]. Sui et al. investigated the role of GSK-3b in NF-
kB regulated neuronal apoptosis [56]. They found that
neurons exposed to HIVADA-macrophage conditioned
medium (MCM) displayed decreased NF-kB activity in a
Tat dependent manner. GSK-3b inhibition through the
lithium or indirubin treatment blocked NF-kB inhibition,
the suppressive binding of RelA to HDAC3, and neuronal
apoptosis [56]. Lithium treatment also inhibits HIV-1
replication of both T- and M-tropic viruses in PBMCs as
well as TNF stimulated J1.1 cells [57]. Therefore, the
inhibition of GSK-3b may have implications for the treat-
ment of neuroAIDS as well as in the inhibition of HIV-1
replication in PBMCs. Future experiments will shed light
on the mechanism of inhibition in various viral strains
and its possible tropism in infected cells.
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PCIs may be ideal candidates for HIV-1 transcription
inhibition, since they target non-essential cellular pro-
teins and avoid emergence of mutant resistant viruses.
We previously reported that r-roscovitine (a first genera-
tion PCI) is a potential inhibitor of HIV-1 replication.
PCIs are among the most promising novel antiviral
agents to emerge over the past few years. In the current
work, we evaluated twenty four cdk inhibitors for their
effect on HIV-1 replication in vitro and found that
alsterpaullone is a potent inhibitor of HIV-1 transcrip-
tion. FACS analysis showed a more dramatic difference
in apoptosis of infected versus uninfected cells, where
the G1 phase population has decreased and the S phase
population has increased. This implies that the G1/S
checkpoint in infected latent cells is either non-existent
or severely defective which may be the ultimate
mechanism of how these cdk inhibitors kill HIV-1
infected cells.
Methods
Cell lines and reagents
The latently HIV-1-infected promyelocytic OM10.1 cell
line, the latently infected promonocytic U1 cell line and
the uninfected corresponding HL-60 and U937 cell
lineages, as well as infected J1-1, ACH2 and their unin-
fected counterparts Jurkat and CEM (12D7) cells were
cultured at 37°C up to 1 × 10
5 cells per ml (early log
phase of growth) in RPMI-1640 medium supplemented
with heat-inactivated fetal bovine serum (10%), strepto-
mycin, penicillin antibiotics (1%) and L-glutamine (1%)
(Gibco/BRL, Gaithersburg, MD, USA). OM10.1, ACH2,
J1-1 contain a single integrated copy of HIV-1 genome,
whereas U1 cells harbor two copies (one wild type and
one mutant) of the viral genome in parental U973 cells.
Cdk inhibitors
The cdk inhibitors used in this study were: aloisine A
(270-385-M001), alsterpaullone (270-275-M001), bohe-
mine (270-390-M001), CGP74514A (270-391-M001),
compound 52 (270-248-M001), 9-cyanopaullone (270-
282-M001), 6-dimethylaminopurine (480-050-M100),
indirubin-3’-monoxime (270-271-M001), 5-iodo-indiru-
bin-3’-monoxime (270-424-M001), N-6-(Δ2-Isopentenyl)-
adenine (350-034-M100), kenpaullone (270-274-M001),
olomoucine (350-013-M005), N9-isopropylolomoucine
(270-397-M001), purvalanol A (270-246-M001), (r)-
roscovitine (350-251-M001), (s)-roscovitine (350-293-
M001) were purchased from Alexis Co. (San Diego, CA,
USA). 6-benzyloxypurine (387606), 2,6-diaminopurine
(247847), 2,6-dichloropurine (D73103), flavone (F2003)
were purchase from Sigma-Aldrich (St. Louis, MO,
USA). Indirubin-3’-monoxime-5-sulfonic acid (402088),
iso-olomoucine (495622), WHI-P180 (681500) were pur-
chased from Calbiochem (La Jolla, CA, USA). The cdk
inhibitor, flavopiridol was a gift from Dr. Ajit Kumar
at The George Washington University Medical Center.
All inhibitors were prepared in 10 mM stock solution.
2,6-dichloropurine and diethylmaleate were dissolved
in ethanol, flavone was dissolved in acetone, flavopiridol
and pyrrolidinedithiocarbamic acid were dissolved
in water and 5-aminosalicylic acid was dissolved in hydro-
chloric acid. All other inhibitors were all dissolved
in DMSO.
Drug screening and cell counting
The initial screening assays included use of HIV-1
infected and uninfected cells that were treated with 24
inhibitors at four concentrations including 0.01, 0.1, 0.5,
1, 5, and 10 μM. Two to six days after treatment
(experiment-dependent), cell viability was primarily
determined by trypan blue exclusion as well as change
of color in media from both infected and uninfected
cells. Cells (~100 cells that did not clump) were counted
for the number of non-viable cells every 24-48 hours.
Subsequent focusing experiments used MTT and flow
data to check for viability and apoptosis.
Protein extracts and immunoblotting
Nuclear and cytoplasmic extracts from uninfected and
infected cells were prepared. Cells were collected,
washed once with PBS and pelleted. Cells were lysed in
a buffer containing containing Tris-HCl pH 7.5, 120
mM NaCl, 5 mM EDTA, 0.5% NP-40, 50 mM NaF, 0.2
mM Na3VO4, 1 mM DTT and one tablet complete pro-
tease inhibitor cocktail per 50 ml. Lysis was performed
under ice-cold conditions, incubated on ice for 30 min-
utes and spun at 4°C for 5 minutes at 14,000 rpm. The
protein concentration for each preparation was deter-
mined with a Bio-Rad protein assay kit (Bio-Rad Labora-
tories, Hercules, CA, USA). Cell extracts were resolved
by SDS PAGE on a 4-20% tris-glycine gel (Invitrogen,
Carlsbad, CA, USA). Proteins were transferred to polyvi-
nylidene difluoride microporous membranes using the
iBlot dry blotting system as described by the manufac-
turer (Invitrogen). Membranes were blocked with Dul-
becco’s phosphate-buffered saline (PBS) 0.1% Tween-20
+ 3% BSA. Primary antibody against specified proteins
was incubated with the membrane in blocking solution
overnight at 4°C. Antibodies against cdk2 (M-2), cyclin
E (M-20), cyclin A (H-432), poly (ADP-ribose) polymer-
ase PARP 1/2 (H-250), caspase-3 (H-277), and actin (C-
11) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Cyclin T1 (ab27963), GSK3-a
(9338), and GSK3-b (9332) antibodies were obtained
from Cell Signaling Technology, Inc. (Danvers, MA,
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Tween-20 and incubated with HRP-conjugated second-
ary antibody for one hour in blocking solution. Presence
of secondary antibody was detected by SuperSignal
West Dura Extended Duration Substrate (Pierce, Rock-
ford, IL, USA). Luminescence was visualized on a Kodak
1D image station (Carestream Helath, Rochester, NY,
USA).
Immunoprecipitation and in vitro kinase assay
For immunoprecipitation (IP) 2 mg of extract from
alsterpaullone-treated (0-5.0 μM) CEM, ACH2, OM10.1
and Jurkat cells were immunoprecipitated at 4°C over-
night with cyclin A antibody. The next day complexes
were precipitated with A/G beads (Calbiochem) for two
hours at 4°C. IPs were washed twice with appropriate
TNE buffer and kinase buffer. Reaction mixtures (20 μl)
contained final concentrations: 40 mM b-glyceropho-
sphate pH 7.4, 7.5 mM MgCl2,7 . 5m ME G T A ,5 %g l y -
cerol, [g-
32P]ATP (0.2 mM, 1 μCi), 50 mM NaF, 1 mM
orthovanadate, and 0.1% (v/v) b-mercaptoethanol. Phos-
phorylation reactions were performed with IP material
and 200 ng of histone H1 in TTK kinase buffer contain-
ing 50 mM HEPES (pH 7.9), 10 mM MgCl2,6m M
EGTA, and 2.5 mM dithiothreitol. Reactions were incu-
bated at 37°C for 1 hour and stopped by the addition of
1v o l u m eo fL a e m m l is a m p l eb u f f e rc o n t a i n i n g5 %
b-mercaptoethanol and ran on a 4-20% SDS-PAGE.
Gels were subjected to autoradiography and quantitation
using a Molecular Dynamics PhosphorImager software
(Amersham Biosciences, Piscataway, NJ, USA).
MTT Viability Assay
Five thousand cells were plated per well in a 96-well
plate and the next day cells were treated with 0.25 μM
alsterpaullone or DMSO. Forty-eight hours later, 10 μl
MTT reagent (50 mg/ml) was added to each well and
plates incubated at 37°C for 2 hours. Next, 100 μlo f
DMSO was added to each well and the plate was shaken
for 15 minutes at room temperature. The assay was read
at 570 nM using a SpectraMax 340 plate reader (Mole-
cular Devices, Sunnyvale, CA, USA).
Flow Cytometry
For cell cycle analysis, cells treated with or without
drugs and subsequently collected by low speed centrifu-
gation washed with PBS without Ca
2+ and Mg
2+ and
then fixed with 70% ethanol. For fluorescence-activated
cell sorting (FACS) analysis, cells were stained with a
mixture of propidium iodide buffer (PBS with Ca
2+ and
Mg
2+,1 0μg/ml RNase A, 0.1% Nonidet P-40, and 50
μg/ml propidium iodide) followed by FACS analysis.
Cells were washed twice with cold PBS without Ca
2+
and Mg
2+, resuspended in 1 × binding buffer (10 mM
HEPES-NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCl2)
and 5 μl of propidium iodide/10
5 cells, and incubated at
room temperature for 15 minutes. Cell histograms were
acquired using CELLQuest software (BD Biosciences,
Bedford, MA, USA) and analyzed by ModFit LT soft-
ware (Verity Software House, Topsham, ME, USA).
Detection of apoptosis through annexin V and PI stain-
ing was done according to the manufacturer’sp r o t o c o l
(BD Pharmingen, San Jose, CA, USA). In brief, cells
were washed three times in PBS and re-suspended in
binding buffer at 1 × 10
6 cells/ml. An aliquot of 1 × 10
5
ells was stained with annexin V-FITC and PI for 15
minutes at room temperature. Analysis was performed
on a BD FacsCalibur flow cytometer. Cells were consid-
ered to be early apoptotic if they exhibited staining for
annexin V, but not PI. The double positive population
was considered to be in the late stage of apoptosis.
PBMC Infection
Phytohemagglutinin-activated PBMCs were kept in cul-
ture with IL-2 for 2 days prior to each infection. Isola-
tion and treatment of PBMCs were performed by
following the guidelines of the Centers for Disease Con-
trol. Approximately 5 × 10
6 PBMCs were infected with
either pNL4-3 (MOI:1) or primary HIV-1 strain (THA/
92/00NSI; 5 ng of p24 gag antigen). Other HIV-1
mutant viruses (AZT, 3TC, TIBO and protease) were
also used for PBMC infections (data not shown). All
viral isolates were obtained from the National Institutes
of Health AIDS Research and Reference Reagent Pro-
gram. After 8 hours of infection, cells were washed and
fresh medium was added. Drug treatment was per-
formed (only once) immediately after the addition of
fresh medium, supernatants from the infected PBMCs
were collected and used directly for reverse transcriptase
(RT) assays or p24 assays.
Luciferase Assay
TZM-bl cells were transfected with pc-Tat (1 μg) using
the Lipofectamine reagent (Invitrogen) according to the
manufacturer’s instructions. TZM-bl cells contain an
integrated copy of the firefly luciferase gene under the
control of the HIV-1 promoter (obtained through the
NIH AIDS Research and Reference Reagent Program).
The next day, cells were treated with DMSO or the
indicated compound at increasing concentrations. Forty-
eight hours post drug treatment, luciferase activity of
the firefly luciferase was measured with the BrightGlo
Luciferase Assay (Promega, Madison, WI, USA) and
luminescence was read from a 96 well plate on an
EG&G Berthold luminometer (Berthold Technologies,
Oak Ridge, TN, USA).
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For RT assays, viral supernatants (10 μl) were incubated
in a 96-well plate with RT reaction mixture containing
1× RT buffer (50 mM Tris-HCl, 1 mM DTT, 5 mM
MgCl2, 20 mM KCl), 0.1% Triton, poly(A) (10
-2 U), poly
(dT) (10
-2 U) and [
3H]TTP. The mixture was incubated
o v e r n i g h ta t3 7 ° Ca n d5μl of the reaction mix was
spotted on a DEAE Filter mat paper (PerkinElmer, Shel-
ton, CT, USA) washed four times with 5% Na2HPO4 and
three times with water, and then dried completely. RT
activity was measured in a Betaplate counter (Wallac,
G a i t h e r s b u r g ,M D ) .F o rp 2 4a s s a y s ,s u p e r n a t a n t sf r o m
infected cells were centrifuged for 8 minutes at 1200 rpm
to remove contaminating cells. p24 levels in the superna-
tants were then assayed by enzyme-linked immunosor-
bent assay (AIDS Vaccine Program, NCI-Frederick
Cancer Research and Development Center, Frederick,
MD, USA) by following the manufacturer’s instructions.
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